SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Akman S) "

Sökning: WFRF:(Akman S)

  • Resultat 1-9 av 9
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Vergallo, A., et al. (författare)
  • Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers
  • 2020
  • Ingår i: Neurobiology of Aging. - : Elsevier BV. - 0197-4580. ; 96, s. 22-32
  • Tidskriftsartikel (refereegranskat)abstract
    • Neuroinflammation, a key early pathomechanistic alteration of Alzheimer's disease, may represent either a detrimental or a compensatory mechanism or both (according to the disease stage). YKL-40, a glycoprotein highly expressed in differentiated glial cells, is a candidate biomarker for in vivo tracking neuroinflammation in humans. We performed a longitudinal study in a monocentric cohort of cognitively healthy individuals at risk for Alzheimer's disease exploring whether age, sex, and the apolipoprotein E ε4 allele affect plasma YKL-40 concentrations. We investigated whether YKL-40 is associated with brain amyloid-β (Aβ) deposition, neuronal activity, and neurodegeneration as assessed via neuroimaging biomarkers. Finally, we investigated whether YKL-40 may predict cognitive performance. We found an age-associated increase of YKL-40 and observed that men display higher concentrations than women, indicating a potential sexual dimorphism. Moreover, YKL-40 was positively associated with memory performance and negatively associated with brain Aβ deposition (but not with metabolic signal). Consistent with translational studies, our results suggest a potentially protective effect of glia on incipient brain Aβ accumulation and neuronal homeostasis. © 2020 Elsevier Inc.
  •  
3.
  • Vergallo, A., et al. (författare)
  • Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
  • 2019
  • Ingår i: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 15:6, s. 764-775
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Blood-based biomarkers of pathophysiological brain amyloid beta (A beta) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. Methods: We investigated whether plasma concentrations of the A beta(1-40)/A beta(1-42) ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain A beta positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-apriori hypothesis study using machine learning. Results: The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma A beta(1-40)/A beta(1-42) ratio. The accuracy is not affected by the apolipoprotein E (APOE) epsilon 4 allele, sex, or age. Discussion: Our results encourage an independent validation cohort study to confirm the indication that the plasma A beta(1-40)/A beta(1-42) ratio, assessed via Simoa, may improve future standard of care and clinical trial design. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
  •  
4.
  •  
5.
  • Palmer, Elizabeth E., et al. (författare)
  • Functional and clinical studies reveal pathophysiological complexity of CLCN4-related neurodevelopmental condition
  • 2023
  • Ingår i: Molecular Psychiatry. - : SPRINGERNATURE. - 1359-4184 .- 1476-5578. ; 28:2, s. 668-697
  • Tidskriftsartikel (refereegranskat)abstract
    • Missense and truncating variants in the X-chromosome-linked CLCN4 gene, resulting in reduced or complete loss-of-function (LOF) of the encoded chloride/proton exchanger ClC-4, were recently demonstrated to cause a neurocognitive phenotype in both males and females. Through international clinical matchmaking and interrogation of public variant databases we assembled a database of 90 rare CLCN4 missense variants in 90 families: 41 unique and 18 recurrent variants in 49 families. For 43 families, including 22 males and 33 females, we collated detailed clinical and segregation data. To confirm causality of variants and to obtain insight into disease mechanisms, we investigated the effect on electrophysiological properties of 59 of the variants in Xenopus oocytes using extended voltage and pH ranges. Detailed analyses revealed new pathophysiological mechanisms: 25% (15/59) of variants demonstrated LOF, characterized by a "shift" of the voltage-dependent activation to more positive voltages, and nine variants resulted in a toxic gain-of-function, associated with a disrupted gate allowing inward transport at negative voltages. Functional results were not always in line with in silico pathogenicity scores, highlighting the complexity of pathogenicity assessment for accurate genetic counselling. The complex neurocognitive and psychiatric manifestations of this condition, and hitherto under-recognized impacts on growth, gastrointestinal function, and motor control are discussed. Including published cases, we summarize features in 122 individuals from 67 families with CLCN4-related neurodevelopmental condition and suggest future research directions with the aim of improving the integrated care for individuals with this diagnosis.
  •  
6.
  • Esir, S., et al. (författare)
  • Magnetic Properties of Annealed CoFe2O4 Nanoparticles Synthesized by the PEG-Assisted Route
  • 2014
  • Ingår i: Journal of Inorganic and Organometallic Polymers and Materials. - : Springer Science and Business Media LLC. - 1574-1443 .- 1574-1451. ; 24:2, s. 424-430
  • Tidskriftsartikel (refereegranskat)abstract
    • Annealed cobalt inverse spinel-type ferrite nanoparticles were synthesized using polyethylene glycol assisted co-precipitation. The structure, magnetic properties and effect of annealing temperature was investigated in detail. Saturation magnetization, coercivity and remanence magnetization were observed to decrease with increasing temperature. The magnetic hysteresis curves supported the proposition that the CoFe2O4 nanoparticles showed ferromagnetic character from 10 to 400 K. Magnetization measurements showed the blocking temperature to be higher than 400 K. Unsaturated magnetization behavior suggested the existence of disordered spins in the surface layer of the CoFe2O4 nanoparticles.
  •  
7.
  • Akman, O., et al. (författare)
  • Magnetic metal nanoparticles coated polyacrylonitrile textiles as microwave absorber
  • 2013
  • Ingår i: Journal of Magnetism and Magnetic Materials. - : Elsevier BV. - 0304-8853 .- 1873-4766. ; 327, s. 151-158
  • Tidskriftsartikel (refereegranskat)abstract
    • Polyacrylonitrile (PAN) textiles with 2 mm thickness are coated with magnetic nanoparticles in coating baths with Ni, Co and their alloys via an electroless metal deposition method. The crystal structure, morphology and magnetic nature of composites are investigated by X-ray Powder diffraction, Scanning Electron Microscopy, and dc magnetization measurement techniques. The frequency dependent microwave absorption measurements have been carried out in the frequency range of 12.4-18 GHz (X and P bands). Diamagnetic and ferromagnetic properties are also investigated. Finally, the microwave absorption of composites is found strongly dependent on the coating time. One absorption peak is observed between 14.3 and 15.8 GHz with an efficient absorption bandwidth of 3.3-4.1 GHz (under -20 dB reflection loss limit). The Reflection loss (RL) can be achieved between -30 and -50 dB. It was found that the RL is decreasing and absorption bandwidth is decreasing with increasing coating time. While absorption peak moves to lower frequencies in Ni coated PAN textile, it goes higher frequencies in Co coated ones. The Ni-Co alloy coated composites have fluctuating curve of absorption frequency with respect to coating time. These results encourage further development of magnetic nanoparticle coated textile absorbers for broadband applications.
  •  
8.
  • Malfatti, Edoardo, et al. (författare)
  • A New Muscle Glycogen Storage Disease Associated with Glycogenin-1 Deficiency
  • 2014
  • Ingår i: Annals of Neurology. - : Wiley. - 0364-5134. ; 76:6, s. 891-898
  • Tidskriftsartikel (refereegranskat)abstract
    • We describe a slowly progressive myopathy in 7 unrelated adult patients with storage of polyglucosan in muscle fibers. Genetic investigation revealed homozygous or compound heterozygous deleterious variants in the glycogenin-1 gene (GYG1). Most patients showed depletion of glycogenin-1 in skeletal muscle, whereas 1 showed presence of glycogenin-1 lacking the C-terminal that normally binds glycogen synthase. Our results indicate that either depletion of glycogenin-1 or impaired interaction with glycogen synthase underlies this new form of glycogen storage disease that differs from a previously reported patient with GYG1 mutations who showed profound glycogen depletion in skeletal muscle and accumulation of glycogenin-1. Ann Neurol 2014;76:891-898
  •  
9.
  • van Huizen, Astrid M., et al. (författare)
  • International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
  • 2022
  • Ingår i: JAMA dermatology. - : American Medical Association (AMA). - 2168-6068 .- 2168-6084. ; 158:5, s. 561-561
  • Tidskriftsartikel (refereegranskat)abstract
    • Importance  A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide.Objective  To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics.Design, Setting, and Participants  Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience).Main Outcomes and Measures  In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree.Results  Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients.Conclusions and Relevance  In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-9 av 9

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy